French Logistics Stock News

ENXTPA:ALLAN
ENXTPA:ALLANBeverage

Lanson BCC H1 EPS Drop To €0.28 Challenges Bullish Growth Narratives

Lanson-BCC (ENXTPA:ALLAN) has put fresh numbers on the table, with first half FY 2025 revenue at €92.05 million and basic EPS at €0.28, alongside trailing twelve month revenue of €259.69 million and EPS of €3.31 that frame how the latest stretch compares with the recent run rate. The company has seen revenue move from €87.80 million and EPS of €0.56 in first half FY 2024 to €167.64 million and EPS of €3.03 in second half FY 2024, giving investors a clear look at how top line scale and per...
ENXTPA:ANTIN
ENXTPA:ANTINCapital Markets

Antin Infrastructure Partners SAS ENXTPA ANTIN Margin Slippage Tests Bullish Growth Narrative

Antin Infrastructure Partners SAS (ENXTPA:ANTIN) has just posted its FY 2025 numbers, with second half revenue of €144.3 million and basic EPS of €0.33, backed by trailing twelve month revenue of €292.5 million and EPS of €0.62. The group has seen revenue move from €318.4 million to €292.5 million on a trailing basis, with EPS shifting from €0.74 to €0.62. FY 2025 first half revenue of €148.2 million and EPS of €0.29 frame the latest half in context, leaving investors weighing solid absolute...
ENXTPA:IDL
ENXTPA:IDLLogistics

ID Logistics Group (ENXTPA:IDL) Earnings Growth Tests Rich P/E Narrative

ID Logistics Group (ENXTPA:IDL) has wrapped up FY 2025 with second half revenue of €1.98b and net income of €40.9m, alongside trailing twelve month revenue of €3.74b and net income of €63.3m that frame the latest run rate. The company has seen revenue move from €1.75b in H2 2024 to €1.98b in H2 2025, while trailing twelve month revenue stepped up from €3.27b to €3.74b and trailing EPS came in at €8.90. This sets the scene for investors to weigh profit trends against how efficiently those...
ENXTPA:ALO
ENXTPA:ALOMachinery

Is It Time To Reassess Alstom (ENXTPA:ALO) After Its Recent Share Price Slide

If you are wondering whether Alstom shares are offering fair value right now, it helps to first look at how the market has been treating the stock over different time frames. Recently, the share price has been under pressure, with a 6.5% decline over the last week, a 15.0% decline over the last month, and a 4.7% decline year to date. This is set against a 5.8% return over 1 year and 12.7% over 3 years, while the 5 year return sits at a 36.4% decline. These moves have come as investors...
ENXTPA:ARG
ENXTPA:ARGIndustrial REITs

Argan (ENXTPA:ARG) Valuation Check After New Lease Secures Full Logistics Portfolio Occupancy

Argan (ENXTPA:ARG) has just secured a nine year lease with JS Logistics for 32,000 sq.m at its Le Coudray Montceaux site, bringing its roughly 4 million sq.m warehouse portfolio back to full occupancy. See our latest analysis for Argan. The lease news lands after a mixed run in the share price, with Argan’s latest €63.8 level sitting alongside a 7 day share price return of 4.78% decline and a 90 day gain of 1.92%. The 1 year total shareholder return of 6.34% contrasts with weaker 3 and 5 year...
ENXTPA:AM
ENXTPA:AMAerospace & Defense

Falcon 10X Raises Stakes For Dassault Aviation And Falcon Franchise Investors

Dassault Aviation société anonyme has presented the Falcon 10X, a new flagship business jet, highlighting major advances in cabin design, materials and flight systems. The aircraft introduces business aviation’s first all composite wing, the NeXus flight deck and next generation digital flight control systems. The Falcon 10X targets the top end of the business jet market, where it will compete with leading large cabin models from established manufacturers. For investors tracking ENXTPA:AM,...
ENXTPA:AIR
ENXTPA:AIRAerospace & Defense

Is There Now An Opportunity In Airbus (ENXTPA:AIR) After The Recent Share Price Pullback

If you are wondering whether Airbus shares are offering fair value right now, you are not alone. Many investors are asking the same question as the stock sits well off its recent highs. The share price closed at €176.92 most recently, with returns of 10.2% over 1 year, 60.5% over 3 years and 87.5% over 5 years. However, the stock has seen a 0.2% slip over 7 days, an 8.4% decline over 30 days and a 13.1% decline year to date. Recent headlines around Airbus have focused on its role as a major...
ENXTPA:HO
ENXTPA:HOAerospace & Defense

How Investors May Respond To Thales (ENXTPA:HO) Expanding AI Air Defense And eSIM Payments Connectivity

In recent days, Thales has launched SkyDefender, a multi-layer integrated air and missile defence system spanning land, sea and space, while also advancing secure connectivity through new quantum-safe 5G security capabilities and eSIM-based partnerships with Verifone and Brazilian payments provider Cielo. Together, these developments highlight how Thales is pairing defence systems, AI and cybersecurity with eSIM-driven payments connectivity to position itself as a core technology partner...
ENXTPA:ENGI
ENXTPA:ENGIIntegrated Utilities

Is It Too Late To Consider Engie (ENXTPA:ENGI) After A 72% One-Year Rally?

If you are wondering whether Engie’s current share price still offers value after a strong run, you are not alone. This article is built to help you think that through clearly. Engie’s stock last closed at €27.04, with returns of 0.1% over 7 days, 5.2% over 30 days, 17.7% year to date and 72.3% over 1 year, while the 3 year and 5 year returns sit at 151.6% and 227.8% respectively. Recent coverage has focused on Engie’s role as a major utilities player in France and Europe, including ongoing...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors

In late February 2026, Sanofi and Regeneron reported that the European Medicines Agency’s CHMP issued positive opinions for Dupixent in young children with chronic spontaneous urticaria and for Acoziborole Winthrop as a single-dose oral treatment for gambiense sleeping sickness, with final EU decisions expected in the months that followed. These CHMP endorsements highlight how Sanofi’s immunology and neglected tropical disease programs may broaden its treatment footprint across both...
ENXTPA:CS
ENXTPA:CSInsurance

How AXA’s 2026 Buyback, Higher Dividend and Earnings Jump At AXA (ENXTPA:CS) Has Changed Its Investment Story

AXA SA has already announced for 2026 a new share repurchase program of up to €1,250 million, authorized by its Board, alongside a higher annual dividend of €2.32 per share and reported past-year net income of €9.80 billion versus €7.89 billion previously. This combination of a sizeable buyback, increased cash returns, and higher net income signals a strong focus on rewarding shareholders and underscores management’s confidence in the business. We’ll now examine how AXA’s sizeable share...
ENXTPA:SW
ENXTPA:SWHospitality

Is Sodexo (ENXTPA:SW) Pricing Make Sense After A 38.3% One Year Share Price Fall

If you are wondering whether Sodexo shares are offering fair value today, this article will walk through what the current price might be implying about the company. Sodexo's share price closed at €44.42, with returns of a 1.6% decline over the last 7 days, a 1.7% decline over 30 days, a 3.4% gain year to date, and a 38.3% decline over the past year. This raises questions about how the market is currently pricing its prospects and risks. Recent news around Sodexo has focused on its role as a...
ENXTPA:VU
ENXTPA:VUElectronic

Assessing Vusion (ENXTPA:VU) After 2025 Results 2026 Guidance And Qualcomm AI Retail Partnership

Vusion (ENXTPA:VU) has been in focus after reporting 2025 sales of €1,472 million with net income of €84.2 million, issuing 2026 earnings guidance, and outlining an AI retail partnership with Qualcomm. See our latest analysis for Vusion. Despite the recent earnings, 2026 guidance and Qualcomm AI retail partnership, Vusion’s 30 day share price return of 12.12% and year to date share price return of 46.94% suggest momentum has been weak, even though the 5 year total shareholder return of...
ENXTPA:DBV
ENXTPA:DBVBiotechs

DBV Technologies (ENXTPA:DBV) Valuation After Positive Phase 3 Peanut Patch Results

DBV Technologies (ENXTPA:DBV) recently reported additional positive data from its Phase 3 VITESSE trial of the VIASKIN Peanut Patch in peanut allergic children, with the study meeting its primary endpoint and showing a statistically significant treatment effect. See our latest analysis for DBV Technologies. The latest clinical update appears to be feeding into stronger momentum, with a 7.3% 1 day share price return and a 36.95% 90 day share price return at €4.04, alongside a very large 1 year...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Veolia Deepens US Waste And Water Role With Long Term Contract Focus

Veolia Environnement announced a new US hazardous waste acquisition, expanding its presence in the North American market. The company is extending its PFAS treatment capabilities across North America to address growing water quality challenges. Veolia and the National Association of Water Companies published a policy white paper calling for large scale water infrastructure investment in the US. Veolia Environnement (ENXTPA:VIE), trading at €32.4, has seen its share price return 7.5% year to...
ENXTPA:GDS
ENXTPA:GDSHealthcare

Ramsay Générale De Santé (ENXTPA:GDS) Valuation Check After Half Year Sales Growth And Narrowing Net Loss

Ramsay Générale de Santé (ENXTPA:GDS) has released half year results to December 31, 2025, reporting sales of €2,589.1 million and a net loss of €34.9 million, both changing compared with a year earlier. See our latest analysis for Ramsay Générale de Santé. The half year update comes after a period where the share price has shown mixed momentum, with a 15.22% 90 day share price return and a 13.49% year to date share price return, yet a 3 year total shareholder return of a 45.36% decline. If...
ENXTPA:74SW
ENXTPA:74SWSoftware

Assessing 74Software (ENXTPA:74SW) Valuation After 2025 Results And New 2028 Growth Targets

Why the 2025 results and 2028 guidance matter for investors 74Software (ENXTPA:74SW) has drawn investor attention after releasing its 2025 full year results alongside fresh guidance for 2028, combining recent performance data with a clearer view of its longer term financial ambitions. On the reported figures, sales for 2025 came in at €707.22 million, while net income was €40.76 million. Basic earnings per share from continuing operations were €1.39, with diluted earnings per share at...
ENXTPA:DBV
ENXTPA:DBVBiotechs

Will Positive Phase 3 VITESSE Peanut Patch Data Change DBV Technologies' (ENXTPA:DBV) Narrative?

DBV Technologies recently presented additional positive data from its successful Phase 3 VITESSE trial of the VIASKIN Peanut Patch for peanut-allergic children aged 4 to 7 at the 2026 AAAAI Annual Meeting in Philadelphia. The data showed clinically meaningful increases in the eliciting dose for treated children versus placebo, highlighting both potential protection against reactions and the risks of remaining untreated. Next, we will examine how these Phase 3 VITESSE results, particularly...
ENXTPA:PLNW
ENXTPA:PLNWSoftware

Assessing Planisware SAS (ENXTPA:PLNW) Valuation After 2026 Growth Guidance And Higher Dividend Proposal

Why Planisware SAS (ENXTPA:PLNW) Is Back on Investors’ Radar Planisware SAS (ENXTPA:PLNW) has caught investor attention after issuing 2026 revenue guidance targeting low double digit growth in constant currencies and proposing a €0.36 dividend per share for 2025, a 16.1% year on year increase. The proposed €0.36 payout represents a 50% distribution of 2025 earnings, so the company is pairing its growth objectives with a commitment to return half of its profits to shareholders. See our latest...
ENXTPA:WLN
ENXTPA:WLNDiversified Financial

Worldline (ENXTPA:WLN) Goodwill Hit Drives €4.2b Loss And Reinforces Bearish Narratives

Worldline FY 2025 results: deep losses meet modest revenue base Worldline (ENXTPA:WLN) has reported fresh numbers for FY 2025, with first half revenue of €2,204.7 million and basic EPS at a loss of €15.05. This compares with a trailing twelve month loss of €18.35 per share on €4,029.9 million of revenue. Over recent periods the company has seen revenue move from €2,368.3 million in the second half of 2023 to €2,288.9 million in the first half of 2024, then to €2,204.7 million in the first...
ENXTPA:IPS
ENXTPA:IPSMedia

Assessing Ipsos (ENXTPA:IPS) Valuation After Launch Of €100 Million Share Buyback Program

Ipsos (ENXTPA:IPS) has launched a €100 million share buyback programme, putting extra attention on how management is choosing to return capital and what that might mean for existing shareholders. See our latest analysis for Ipsos. The buyback follows a series of announcements, including a proposed €2.00 per share dividend, recent full year 2025 results, and changes in senior leadership and technology roles, with the share price currently at €36.92. The 30 day share price return of 11.81% and...
ENXTPA:ATO
ENXTPA:ATOIT

Atos (ENXTPA:ATO) EPS Loss Revives Bearish Narrative On Turnaround Durability

Intro Atos (ENXTPA:ATO) has just reported its FY 2025 results with first half revenue of €4.0b and a basic EPS loss of €37.36, alongside net income excluding extra items of a €696m loss. Over recent reporting periods the company has seen revenue move from €5.0b in the first half of 2024 to €4.6b in the second half of 2024 and €4.0b in the first half of 2025, while EPS has swung from a €174,754.66 loss in early 2024 to a €1,531.47 gain in late 2024 before landing at a €37.36 loss most...
ENXTPA:SOP
ENXTPA:SOPIT

Assessing Sopra Steria Group’s Valuation As 2025 Earnings And Dividend Rise Despite Softer Sales

Sopra Steria Group (ENXTPA:SOP) is back in focus after reporting 2025 earnings that combined lower sales with higher net income and earnings per share, along with a proposed dividend increase for shareholders. See our latest analysis for Sopra Steria Group. The share price reaction has been positive around these results, with a 1-day share price return of 3.86% and a 7-day share price return of 4.65% at €137.3. However, the year-to-date share price return of an 8.95% decline and the 1-year...
ENXTPA:EL
ENXTPA:ELMedical Equipment

Is EssilorLuxottica (ENXTPA:EL) Attractive After Recent Share Price Weakness And Mixed Valuation Signals

If you are wondering whether EssilorLuxottica Société anonyme is priced attractively right now, looking closely at what you are paying for each euro of underlying business is a good place to start. The share price last closed at €212.80, with a 5.5% decline over the past 7 days, an 18.3% decline over 30 days, a 19.8% decline year to date, but gains of 40.6% over 3 years and 64.6% over 5 years. These moves sit against a backdrop of ongoing global interest in vision care and eyewear brands,...